NCT00534001 · STUDY IN CONTEXT

Bupropion in Helping Adults Stop Smoking

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Prequit Change in Cigarettes Per Day

Excludes participants with missing data (2 in Arm 1, 3 in Arm 2)

→

secondary · POSTED

Bioverified 4-week continuous abstinence

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-cervical-cancer
nct id: NCT00534001
trial label: Bupropion in Helping Adults Stop Smoking
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 2
harms Count: 2
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer
nct id
NCT00534001
outcome key
om-0000
source section id
NCT00534001-om-0000
source outcome index
0
endpoint
Prequit Change in Cigarettes Per Day
endpoint definition
Prequit Change in Cigarettes Per Day
time origin
3-Week PreQuit Drug Manipulation Phase
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Excludes participants with missing data (2 in Arm 1, 3 in Arm 2)
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer
nct id
NCT00534001
outcome key
om-0001
source section id
NCT00534001-om-0001
source outcome index
1
endpoint
Abstinence
endpoint definition
Bioverified 4-week continuous abstinence
time origin
4 weeks
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer
nct id
NCT00534001
outcome key
om-0000
arm key
OG000
arm label
Arm I (1-week run-in)
regimen
Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4. bupropion hydrochloride: Given orally placebo: Given orally
analyzed count
46
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00534001-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer
nct id
NCT00534001
outcome key
om-0000
arm key
OG001
arm label
Arm II (4-week run-in)
regimen
Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4. bupropion hydrochloride: Given orally
analyzed count
46
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00534001-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer
nct id
NCT00534001
outcome key
om-0001
arm key
OG000
arm label
Arm I (1-week run-in)
regimen
Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4. bupropion hydrochloride: Given orally placebo: Given orally
analyzed count
48
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00534001-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer
nct id
NCT00534001
outcome key
om-0001
arm key
OG001
arm label
Arm II (4-week run-in)
regimen
Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4. bupropion hydrochloride: Given orally
analyzed count
47
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00534001-om-0001#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer
nct id
NCT00534001
harm key
EG000
source section id
NCT00534001-ae
event group key
EG000
event group label
Arm I (1-week run-in)
serious affected
0
serious at risk
48
other affected
48
other at risk
48
frequency threshold
5
collection period
8 weeks
event definition
Only participant-volunteered side effects were noted.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-cervical-cancer
nct id
NCT00534001
harm key
EG001
source section id
NCT00534001-ae
event group key
EG001
event group label
Arm II (4-week run-in)
serious affected
0
serious at risk
47
other affected
47
other at risk
47
frequency threshold
5
collection period
8 weeks
event definition
Only participant-volunteered side effects were noted.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice